Effect of thiazolidine LPSF SF29 on the growth and morphology of Trypanosoma cruzi

Int J Antimicrob Agents. 2013 Feb;41(2):183-7. doi: 10.1016/j.ijantimicag.2012.09.018. Epub 2012 Dec 4.

Abstract

Chagas disease, caused by the protozoan Trypanosoma cruzi, is an endemic illness in Latin America. Efforts have been made by several groups to develop new effective and safe anti-T. cruzi drugs. In the present work, we show that thiazolidine LPSF SF29 inhibited growth of the epimastigote and amastigote forms and caused lysis in the trypomastigote form of T. cruzi, leading to death of the protozoan. Mitochondrial dysfunction was also observed. The thiazolidine induced ultrastructural alterations such as detachment of the flagellar membrane, intense mitochondrial swelling, formation of myelin-like figures and the appearance of autophagosomes. Taken together, these results suggest that this new thiazolidine is active against T. cruzi and constitutes a promising drug for the therapy of Chagas disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiprotozoal Agents / pharmacology*
  • Cell Survival / drug effects
  • Humans
  • Latin America
  • Microscopy, Electron
  • Mitochondria / drug effects
  • Mitochondria / physiology
  • Thiazolidines / pharmacology*
  • Trypanosoma cruzi / drug effects*
  • Trypanosoma cruzi / growth & development
  • Trypanosoma cruzi / ultrastructure

Substances

  • Antiprotozoal Agents
  • Thiazolidines